An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.
Awards, honors, prizes and achievements for the month of March.
Back to News
Weill Cornell MedicineOffice of External Affairs Phone: (646) 962-9476